UroGen Pharma Ltd (NASDAQ: URGN) on Friday, plunged -3.64% from the previous trading day, before settling in for the closing price of $13.73. Within the past 52 weeks, URGN’s price has moved between $10.60 and $20.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 13144.25% annually for the last half of the decade. The company achieved an average annual earnings per share of 2.16%. With a float of $38.12 million, this company’s outstanding shares have now reached $42.11 million.
In an organization with 201 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.87%, operating margin of -93.74%, and the pretax margin is -128.98%.
UroGen Pharma Ltd (URGN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of UroGen Pharma Ltd is 9.49%, while institutional ownership is 97.78%. The most recent insider transaction that took place on Jun 10 ’24, was worth 67,401. In this transaction Chief Medical Officer of this company sold 5,153 shares at a rate of $13.08, taking the stock ownership to the 144,284 shares. Before that another transaction happened on Mar 18 ’24, when Company’s Chief Medical Officer sold 12,000 for $14.05, making the entire transaction worth $168,600. This insider now owns 139,437 shares in total.
UroGen Pharma Ltd (URGN) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.68 earnings per share (EPS) for the period topping the consensus outlook (set at -0.85) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.16% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
UroGen Pharma Ltd (URGN) is currently performing well based on its current performance indicators. A quick ratio of 7.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.27, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -2.89 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.5 million. That was better than the volume of 0.47 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.63%. Additionally, its Average True Range was 0.77.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 26.04%, which indicates a significant increase from 3.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.50% in the past 14 days, which was lower than the 73.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.46, while its 200-day Moving Average is $15.13. However, in the short run, UroGen Pharma Ltd’s stock first resistance to watch stands at $13.61. Second resistance stands at $14.00. The third major resistance level sits at $14.23. If the price goes on to break the first support level at $12.99, it is likely to go to the next support level at $12.76. The third support level lies at $12.37 if the price breaches the second support level.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
Market capitalization of the company is 557.12 million based on 23,454K outstanding shares. Right now, sales total 82,710 K and income totals -102,240 K. The company made 21,850 K in profit during its latest quarter, and -33,400 K in sales during its previous quarter.
